IFNB1 and myeloid sarcoma: Published data on the use of pulsed corticosteroids, interferon-beta, and glatiramer acetate show that these agents cannot prevent rebound activity, and breakthrough disease activity occurs in a proportion of patients with MS treated with either DMF or teriflunomide (21–24).